PBLS

27.4400.67%
AA

Alexis A. Borisy

Independent Chairman

Mr. Alexis A. Borisy, A.M., serves as Chairman at Nextech Invest Ltd. He is Founder of Curie Bio Operations, LLC and also serves as an Operating Chairman since October 2024; he also served as Operating Chairman until October 2024. He serves as Chair of Museum Of Science and as Board Observer of the Boston Museum of Science. At Celsius Therapeutics, Inc., he is Co-Founder and also serves as Executive Chairman of the Board; he also served as Interim Chief Executive Officer until June 11, 2019. He Founded Tango Therapeutics, Inc. and also served as Lead Independent Director since January 8, 2026 until May 13, 2026; at the company, he also served as Independent Chairman from August 2021 to January 8, 2026, as Independent Director from March 2017 to January 8, 2026 and as President. He is Co-Founder of Relay Therapeutics, Inc. and also serves as Independent Chairman since April 2015; at the company, he also served as Executive Chairman, as Interim Chief Executive Officer from 2016 to April 4, 2017 and as Partner until April 5, 2017. At Revolution Medicines, Inc., he serves as Lead Independent Director and previously served as Independent Director from November 2014. He is Founder of Warp Drive Bio, LLC and also serves as Executive Chairman since July 2013; he also served as Interim Chief Executive Officer until July 2013. He serves as Independent Non-Employee Director of Parabilis Medicines, Inc. since February 2024. He serves as Director of PhenoTech, Inc. He serves as Director of Thrive Earlier Detection Corp. He serves as Director of Nextech Invest since 2022. At the National Venture Capital Association, he serves as Chair of the Board of Directors since May 16, 2018 and as a Director since May 14, 2014; he also served as Chair-Elect from May 10, 2017. He is Co-Founder of IDRX, Inc. He serves as Member of the Advisory Board of Dataspora LLC. Previously, he was Co-Founder of Blueprint Medicines Corporation and also served as Director from April 2011 to July 18, 2025; at the company, he also served as Interim Chief Executive Officer from May 2013 to July 2014. He served as Independent Director of OPKO Health, Inc. from May 9, 2022 to March 28, 2024. He was Founder of EQRx, Inc. and also served as Executive Chairman of the Board of Directors from September 1, 2021 to July 31, 2023; he also served as Chief Executive Officer and Chairman from August 2019 to September 1, 2021. He served as an Independent Director at Magenta Therapeutics, Inc. since January 2016 until leaving the firm in June 2022. He was a Partner at Third Rock Ventures, LLC from 2010 to June 2019 and served as its Entrepreneur-in-Residence, having joined the firm in 2009. He co-founded Foundation Medicine, Inc., where he served as Founding Advisor & Independent Director until July 31, 2018; at the company, he also served as Chairman from May 12, 2011 to February 6, 2017, as Chief Executive Officer from 2010 to May 12, 2011 and as Interim Chief Executive Officer from 2009. He served as Non-Employee Director of Editas Medicine, Inc. from November 2013 to March 27, 2018. He served as Chairman of Forma Therapeutics, Inc. from 2007 to 2012 and as a Director from 2009 to 2011. He also served as Director of Forma Therapeutics Holdings, Inc. He co-founded CombinatoRx Incorporated in 2000, where he served as President and Chief Executive Officer until 2009 and as a Director. He is Co-Founder of Zalicus Inc., where he served as Chief Executive Officer, President and Director since March 2000. He was an Associate Consultant at Vertex Partners from 1995 to 1998 and an Intern at Nicolet Scientific Instruments Ltd. from 1990 to 1992. He also served as a Board Member of the Biotechnology Innovation Organization. He is Chairman of several NASDAQ listed companies. He was honored as the MIT Technology Review Innovator of the Year in 2003, the New England Entrepreneur of the Year in Life Sciences and as a Presidential Scholar in 1989. He has authored numerous patents and scientific publications. He holds an M.A. in Chemical Biology & Chemistry from Harvard University, where he was a Howard Hughes Predoctoral Fellow and did his graduate work in the laboratory of Dr. Stuart Schreiber and a B.A. in Chemistry from The University of Chicago.

Positions